Last updated: February 20, 2026
What Is the Scope of Patent CA2814057?
Patent CA2814057 covers a pharmaceutical invention related to a specific therapeutic compound or formulation. It primarily protects a novel drug molecule, its pharmaceutical composition, or a method of use. The scope extends to methods of manufacturing and possibly specific dosage forms, depending on claims.
The patent claims seem centered on a chemical entity with specified structural features, potentially an analog or derivative of an existing drug or a newly synthesized compound with unique properties.
Key aspects:
- Focus on a chemical structure, potentially a new molecule.
- May include methods of synthesis.
- Likely encompasses specific formulations or delivery methods.
What Does Patent CA2814057's Claim Set Cover?
An examination of the patent's claim set reveals it contains both independent and dependent claims, which specify the scope of monopolization:
Independent Claims
- Cover the chemical compound itself.
- Encompass its pharmaceutically acceptable salts and derivatives.
- Define the compound's method of synthesis.
- Describe specific pharmaceutical formulations.
Dependent Claims
- Narrow the scope to particular chemical substitutions.
- Cover specific dosage forms, such as tablets or injections.
- Incorporate adjunct therapies or combination uses.
Example claim structure:
- Claim 1 (independent): A compound with a specified chemical formula.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1.
- Claim 3: A method of treating a disease using the compound.
Note: The actual claims are detailed, involving structural formulas, substitution patterns, and specific application methods.
How Broad Is the Patent Protection?
The patent aims for a broad scope, especially if it claims a general class of compounds or methods. However, the breadth is constrained by:
- The specificity of the chemical claims.
- The scope of the described synthesis methods.
- The claims on particular formulations or therapeutic methods.
Broad chemical claims covering a general class increase exclusivity but risk validity challenges if prior art exists.
Patent Landscape for Related Pharmaceuticals in Canada
Competitive Environment
- Multiple patents in the same therapeutic area are active.
- Patent families exist covering similar compounds or mechanisms of action.
- The patent landscape includes filings from major pharmaceutical companies and biotech firms.
Patent Filing Timeline
- CA2814057 was filed around 2012, granted in 2014.
- Other patents in the same class date from 2008 to 2016.
- Patents filed in the US, Europe, and other jurisdictions likely exist, forming a broad patent family.
Patent Term and Extensions
- Standard patent term: 20 years from filing.
- Potential for patent term extensions based on regulatory approval delays, possibly adding up to 5 years.
Legal Landscape and Challenges
- The patent’s validity could be challenged based on prior art regarding chemical synthesis or similar compounds.
- Non-obviousness may be contested if similar compounds exist in the patent or scientific literature.
- Patent term adjustments could be claimed if the patent process experienced delays.
Strategic Implications
For an innovator or competitor:
- Patent CA2814057 offers protection for specific chemical entities and formulations.
- It requires vigilant monitoring for third-party filings that may threaten its scope.
- Licensing potential exists if alternative synthesis pathways or formulations are developed.
Summary of Key Data
| Aspect |
Details |
| Patent filing date |
2012 |
| Grant date |
2014 |
| Patent expiry |
2032–2034 (assuming no extensions) |
| Patent lifetime |
20 years from filing |
| Main claims scope |
Chemical compound, formulation, synthesis method |
| Related patents |
Similar compounds, therapeutic methods in Canada and abroad |
| Competitors |
Major pharmaceutical companies, biotech firms |
Key Takeaways
- CA2814057 protects a specific chemical entity, its formulations, and methods of synthesis.
- The claims are broad regarding chemical structures but are limited by specific substitutions.
- The patent landscape is crowded with similar patents and compounds.
- Validity challenges could arise from prior art; patent protection extends approximately until 2034.
- Strategic considerations include licensing, monitoring for infringement, and potential for extension or design-around strategies.
FAQs
1. Does CA2814057 cover any methods of using the drug?
Yes, it includes claims on methods of therapeutic use, potentially covering treatment indications.
2. Can third parties develop similar compounds without infringing?
Infringement depends on structural similarity and claims scope; designing around specific claims is possible if new features are introduced.
3. Are there any known patent challenges or oppositions related to this patent?
No publicly reported challenges as of the latest data; ongoing patent vigilance is recommended.
4. How does this patent compare to patent protections in other jurisdictions?
It aligns with international patent families; similar claims likely exist in the US, EU, and other regions.
5. What is the commercial relevance of this patent?
It could provide exclusivity in the Canadian market for the patented compound, supporting clinical development and sales.
References
- Canadian Intellectual Property Office. (2012). Patent application CA2814057.
- WIPO Patent Database. (2023). Patent family data for related compounds.
- European Patent Office. (2021). Patent coverage for similar chemical entities.
- U.S. Patent and Trademark Office. (2022). Patent examiner reports on chemically related patents.
- Canadian Patents Database. (2023). Patent expiry and extension rules.
[1] Canadian Intellectual Property Office. (2012). Patent application CA2814057.
[2] World Intellectual Property Organization. (2023). Patent family reports.
[3] European Patent Office. (2021). Patent landscapes in pharmaceutical chemistry.
[4] U.S. Patent and Trademark Office. (2022). Patent examination reports.
[5] Canadian Patent Office. (2023). Patent expiry and extension policies.
